Intra-arterial thrombolysis in acute ischaemic stroke
Several thrombolytic agents for the treatment of acute ischaemic stroke have been examined; however, to date, only the i.v. administration of recombinant tissue plasminogen activator is licensed in Australia. Although no trials directly comparing intra‐arterial and i.v. delivery of thrombolytics exi...
Gespeichert in:
| Veröffentlicht in: | Internal medicine journal 2005-05, Vol.35 (5), p.300-302 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 302 |
|---|---|
| container_issue | 5 |
| container_start_page | 300 |
| container_title | Internal medicine journal |
| container_volume | 35 |
| creator | Jones, M. M. Nogajski, J. H. Faulder, K. Harrington, T. Ng, P. Storey, C. E. |
| description | Several thrombolytic agents for the treatment of acute ischaemic stroke have been examined; however, to date, only the i.v. administration of recombinant tissue plasminogen activator is licensed in Australia. Although no trials directly comparing intra‐arterial and i.v. delivery of thrombolytics exist, intra‐arterial thrombolysis has several potential advantages, including angiographic assessment of the thrombus and the site of occlusion and collateral circulation, improved recanalization, and delivery of higher local concentrations of thrombolytic agents and extending the therapeutic time window for treatment. We conducted a retrospective audit of our experience with the use of intra‐arterial urokinase to treat acute ischaemic stroke at an Australian tertiary‐care hospital between June 1993 and June 2003. We examined time from stroke onset to assessment, computerized tomography scan, cerebral angiography and thrombolysis, anatomical classification of intra‐arterial thrombus, rates of symptomatic intracerebral haemorrhage, and clinical outcome at 3 months. We believe that in carefully selected individuals in appropriate centres of expertise, intra‐arterial thrombolytic therapy holds great promise. (Intern Med J 2005; 35: 300–302) |
| doi_str_mv | 10.1111/j.1445-5994.2005.00830.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67765320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67765320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4340-f49c0d55efbc703d2e4c5bb406157c99a70c1dbc43cb3b1db46f8244aa408a033</originalsourceid><addsrcrecordid>eNqNkFtPwjAYhhujEUT_gtmN3m1-XdsdEm8MKqCgCfFw2XSlC4WNYTsi_HsLI3Brb_omfd7264OQhyHAbt3NAkwp81ma0iAEYAFAQiBYn6D24eB0l6kPKZAWurB2BoBjktJz1MIsoQxj2kZssKiN8IWpldGi8OqpqcqsKjZWW08vPCFXtfK0lVOhSi09W5tqri7RWS4Kq672ewd9Pj99dPv-8L036D4MfUkJBT-nqYQJYyrPZAxkEioqWZZRiDCLZZqKGCSeZA6WGclcolGehJQKQSERQEgH3Tb3Lk31s1K25qUbRRWFWKhqZXkUxxEjITgwaUBpKmuNyvnS6FKYDcfAt8r4jG_N8K0ZvlXGd8r42lWv92-sslJNjsW9Iwfc7AFhpShyIxZS2yMXxQnDaeS4-4b71YXa_HsAPhi9uODqflPXtlbrQ12YufsmiRn_fuvx_vj1a_Q4HvKE_AHuSZXa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67765320</pqid></control><display><type>article</type><title>Intra-arterial thrombolysis in acute ischaemic stroke</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Jones, M. M. ; Nogajski, J. H. ; Faulder, K. ; Harrington, T. ; Ng, P. ; Storey, C. E.</creator><creatorcontrib>Jones, M. M. ; Nogajski, J. H. ; Faulder, K. ; Harrington, T. ; Ng, P. ; Storey, C. E.</creatorcontrib><description>Several thrombolytic agents for the treatment of acute ischaemic stroke have been examined; however, to date, only the i.v. administration of recombinant tissue plasminogen activator is licensed in Australia. Although no trials directly comparing intra‐arterial and i.v. delivery of thrombolytics exist, intra‐arterial thrombolysis has several potential advantages, including angiographic assessment of the thrombus and the site of occlusion and collateral circulation, improved recanalization, and delivery of higher local concentrations of thrombolytic agents and extending the therapeutic time window for treatment. We conducted a retrospective audit of our experience with the use of intra‐arterial urokinase to treat acute ischaemic stroke at an Australian tertiary‐care hospital between June 1993 and June 2003. We examined time from stroke onset to assessment, computerized tomography scan, cerebral angiography and thrombolysis, anatomical classification of intra‐arterial thrombus, rates of symptomatic intracerebral haemorrhage, and clinical outcome at 3 months. We believe that in carefully selected individuals in appropriate centres of expertise, intra‐arterial thrombolytic therapy holds great promise. (Intern Med J 2005; 35: 300–302)</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/j.1445-5994.2005.00830.x</identifier><identifier>PMID: 15845114</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Pty</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Brain Ischemia - drug therapy ; Cerebral Infarction - drug therapy ; Female ; General aspects ; Humans ; Infarction, Anterior Cerebral Artery - drug therapy ; Infarction, Middle Cerebral Artery - drug therapy ; intra-arterial thrombolysis ; Medical sciences ; Middle Aged ; Neurology ; Plasminogen Activators - therapeutic use ; stroke ; Stroke - drug therapy ; thrombolysis ; Thrombolytic Therapy - methods ; Urokinase-Type Plasminogen Activator - therapeutic use ; Vascular diseases and vascular malformations of the nervous system ; Vertebrobasilar Insufficiency - drug therapy</subject><ispartof>Internal medicine journal, 2005-05, Vol.35 (5), p.300-302</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4340-f49c0d55efbc703d2e4c5bb406157c99a70c1dbc43cb3b1db46f8244aa408a033</citedby><cites>FETCH-LOGICAL-c4340-f49c0d55efbc703d2e4c5bb406157c99a70c1dbc43cb3b1db46f8244aa408a033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1445-5994.2005.00830.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1445-5994.2005.00830.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16785196$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15845114$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, M. M.</creatorcontrib><creatorcontrib>Nogajski, J. H.</creatorcontrib><creatorcontrib>Faulder, K.</creatorcontrib><creatorcontrib>Harrington, T.</creatorcontrib><creatorcontrib>Ng, P.</creatorcontrib><creatorcontrib>Storey, C. E.</creatorcontrib><title>Intra-arterial thrombolysis in acute ischaemic stroke</title><title>Internal medicine journal</title><addtitle>Intern Med J</addtitle><description>Several thrombolytic agents for the treatment of acute ischaemic stroke have been examined; however, to date, only the i.v. administration of recombinant tissue plasminogen activator is licensed in Australia. Although no trials directly comparing intra‐arterial and i.v. delivery of thrombolytics exist, intra‐arterial thrombolysis has several potential advantages, including angiographic assessment of the thrombus and the site of occlusion and collateral circulation, improved recanalization, and delivery of higher local concentrations of thrombolytic agents and extending the therapeutic time window for treatment. We conducted a retrospective audit of our experience with the use of intra‐arterial urokinase to treat acute ischaemic stroke at an Australian tertiary‐care hospital between June 1993 and June 2003. We examined time from stroke onset to assessment, computerized tomography scan, cerebral angiography and thrombolysis, anatomical classification of intra‐arterial thrombus, rates of symptomatic intracerebral haemorrhage, and clinical outcome at 3 months. We believe that in carefully selected individuals in appropriate centres of expertise, intra‐arterial thrombolytic therapy holds great promise. (Intern Med J 2005; 35: 300–302)</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Brain Ischemia - drug therapy</subject><subject>Cerebral Infarction - drug therapy</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Infarction, Anterior Cerebral Artery - drug therapy</subject><subject>Infarction, Middle Cerebral Artery - drug therapy</subject><subject>intra-arterial thrombolysis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Plasminogen Activators - therapeutic use</subject><subject>stroke</subject><subject>Stroke - drug therapy</subject><subject>thrombolysis</subject><subject>Thrombolytic Therapy - methods</subject><subject>Urokinase-Type Plasminogen Activator - therapeutic use</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Vertebrobasilar Insufficiency - drug therapy</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkFtPwjAYhhujEUT_gtmN3m1-XdsdEm8MKqCgCfFw2XSlC4WNYTsi_HsLI3Brb_omfd7264OQhyHAbt3NAkwp81ma0iAEYAFAQiBYn6D24eB0l6kPKZAWurB2BoBjktJz1MIsoQxj2kZssKiN8IWpldGi8OqpqcqsKjZWW08vPCFXtfK0lVOhSi09W5tqri7RWS4Kq672ewd9Pj99dPv-8L036D4MfUkJBT-nqYQJYyrPZAxkEioqWZZRiDCLZZqKGCSeZA6WGclcolGehJQKQSERQEgH3Tb3Lk31s1K25qUbRRWFWKhqZXkUxxEjITgwaUBpKmuNyvnS6FKYDcfAt8r4jG_N8K0ZvlXGd8r42lWv92-sslJNjsW9Iwfc7AFhpShyIxZS2yMXxQnDaeS4-4b71YXa_HsAPhi9uODqflPXtlbrQ12YufsmiRn_fuvx_vj1a_Q4HvKE_AHuSZXa</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Jones, M. M.</creator><creator>Nogajski, J. H.</creator><creator>Faulder, K.</creator><creator>Harrington, T.</creator><creator>Ng, P.</creator><creator>Storey, C. E.</creator><general>Blackwell Science Pty</general><general>Blackwell Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>Intra-arterial thrombolysis in acute ischaemic stroke</title><author>Jones, M. M. ; Nogajski, J. H. ; Faulder, K. ; Harrington, T. ; Ng, P. ; Storey, C. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4340-f49c0d55efbc703d2e4c5bb406157c99a70c1dbc43cb3b1db46f8244aa408a033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Brain Ischemia - drug therapy</topic><topic>Cerebral Infarction - drug therapy</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Infarction, Anterior Cerebral Artery - drug therapy</topic><topic>Infarction, Middle Cerebral Artery - drug therapy</topic><topic>intra-arterial thrombolysis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Plasminogen Activators - therapeutic use</topic><topic>stroke</topic><topic>Stroke - drug therapy</topic><topic>thrombolysis</topic><topic>Thrombolytic Therapy - methods</topic><topic>Urokinase-Type Plasminogen Activator - therapeutic use</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Vertebrobasilar Insufficiency - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, M. M.</creatorcontrib><creatorcontrib>Nogajski, J. H.</creatorcontrib><creatorcontrib>Faulder, K.</creatorcontrib><creatorcontrib>Harrington, T.</creatorcontrib><creatorcontrib>Ng, P.</creatorcontrib><creatorcontrib>Storey, C. E.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, M. M.</au><au>Nogajski, J. H.</au><au>Faulder, K.</au><au>Harrington, T.</au><au>Ng, P.</au><au>Storey, C. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intra-arterial thrombolysis in acute ischaemic stroke</atitle><jtitle>Internal medicine journal</jtitle><addtitle>Intern Med J</addtitle><date>2005-05</date><risdate>2005</risdate><volume>35</volume><issue>5</issue><spage>300</spage><epage>302</epage><pages>300-302</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Several thrombolytic agents for the treatment of acute ischaemic stroke have been examined; however, to date, only the i.v. administration of recombinant tissue plasminogen activator is licensed in Australia. Although no trials directly comparing intra‐arterial and i.v. delivery of thrombolytics exist, intra‐arterial thrombolysis has several potential advantages, including angiographic assessment of the thrombus and the site of occlusion and collateral circulation, improved recanalization, and delivery of higher local concentrations of thrombolytic agents and extending the therapeutic time window for treatment. We conducted a retrospective audit of our experience with the use of intra‐arterial urokinase to treat acute ischaemic stroke at an Australian tertiary‐care hospital between June 1993 and June 2003. We examined time from stroke onset to assessment, computerized tomography scan, cerebral angiography and thrombolysis, anatomical classification of intra‐arterial thrombus, rates of symptomatic intracerebral haemorrhage, and clinical outcome at 3 months. We believe that in carefully selected individuals in appropriate centres of expertise, intra‐arterial thrombolytic therapy holds great promise. (Intern Med J 2005; 35: 300–302)</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Pty</pub><pmid>15845114</pmid><doi>10.1111/j.1445-5994.2005.00830.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1444-0903 |
| ispartof | Internal medicine journal, 2005-05, Vol.35 (5), p.300-302 |
| issn | 1444-0903 1445-5994 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67765320 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Biological and medical sciences Brain Ischemia - drug therapy Cerebral Infarction - drug therapy Female General aspects Humans Infarction, Anterior Cerebral Artery - drug therapy Infarction, Middle Cerebral Artery - drug therapy intra-arterial thrombolysis Medical sciences Middle Aged Neurology Plasminogen Activators - therapeutic use stroke Stroke - drug therapy thrombolysis Thrombolytic Therapy - methods Urokinase-Type Plasminogen Activator - therapeutic use Vascular diseases and vascular malformations of the nervous system Vertebrobasilar Insufficiency - drug therapy |
| title | Intra-arterial thrombolysis in acute ischaemic stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T12%3A26%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intra-arterial%20thrombolysis%20in%20acute%20ischaemic%20stroke&rft.jtitle=Internal%20medicine%20journal&rft.au=Jones,%20M.%20M.&rft.date=2005-05&rft.volume=35&rft.issue=5&rft.spage=300&rft.epage=302&rft.pages=300-302&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/j.1445-5994.2005.00830.x&rft_dat=%3Cproquest_cross%3E67765320%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67765320&rft_id=info:pmid/15845114&rfr_iscdi=true |